Press release: dupixent® (dupilumab) late-breaking data at aad show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

Dupixent ® (dupilumab) late-breaking data at aad show significant improvements in signs and symptoms of m oderate-to-severe a topic h and and f oot d ermatitis

REGN Ratings Summary

REGN Quant Ranking